Let collaboration with MaxCyte® be the spark that lights your way.
At MaxCyte, we share your passion for the discovery, development and manufacturing of next generation therapies, harnessing the power of living cells to transform lives.
We know that every research journey is full of challenges, but we believe that transfecting cells shouldn’t be one of them. With over 20 years of cell engineering expertise using our best-in-class electroporation technology, we’ve perfected the art of the cell-engineering workflow. We want to share this with you to enable pioneering research and chart your most direct course to success.
A voyage filled with scientific advances
MaxCyte founded to commercialize Flow Electroporation® technology
Entered license agreements with researchers developing human cell therapies
Launch of the ExPERT™ technology platform
MaxCyte is the technology of choice for cell-engineering experts, driving a new generation of cell-based therapies.
We have collaborated in 35 clinical trials driven by leaders in pharma and biotech to develop treatments for an expanding range of indications including cancer, central nervous system disorders and rare genetic diseases.
Who We Serve
We partner with leading academic institutions, translational centers and biopharmaceutical companies worldwide, engaging in cell and gene therapy, drug discovery, gene editing and biomanufacturing.
What we offer
MaxCyte technology enables non-viral engineering of a vast array of cell types, including human primary cells, delivering virtually any molecule, at any scale.
We offer an unparalleled combination of efficiency, reproducibility and high cell viability, facilitating rapid, non-viral cell engineering.
We understand and help solve scientific problems.
Our approach is collaborative, with the goal of rapidly accelerating our partners’ discoveries to commercial use cost-effectively and with lowered risk.
And with a broad intellectual property portfolio we offer our partners access to cutting edge technology.
One Unifying Voice
Now is the time to speak up.
At MaxCyte, we denounce racism, inequality, violence, coercion and discrimination in all forms.
We are committed to fostering workplace development, diversity, and inclusion (WDDI) within our own organization and across the biotechnology industry. We are dedicated to develop a diverse and talented global workforce, and understand the value that diversity contributes to the culture and success of any business. Diverse teams enhance collaboration, are more accepting of differences, and are also more effective in the global environment in which we operate, enabling the promise of next-generation cell and gene-editing therapies around the globe.
To that end, we affirmatively support the WDDI Principles adopted by the Biotechnology Innovation Organization (BIO), and pledge to do our part to foster diversity and inclusion among our employees, customers, patients and the communities where we operate.
We acknowledge as a company that we must hold true to our values and treat each other with acceptance, care and respect — and we must hold one another accountable. We must speak up when we see examples of racism, discrimination, and violence — and we must help break down barriers.
Now is the time to speak up. Now is the time to engage.